Abstract
This perspective on Deng et al. (beginning on p. 424 in this issue of the journal) examines the link between NF-kappaB and lung tumorigenesis. Experiments in genetically engineered mouse models of lung cancers are elucidating protumorigenic roles of NF-kappaB activation in lung cancer pathogenesis. Our growing understanding of the tumor-promoting NF-kappaB downstream effector pathways could lead to the development of novel approaches for lung cancer therapy and chemoprevention.